Praxis Precision Medicines Insider Option Grant: 10.5K Shares to Director

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Dean J. Mitchell received a new stock option grant for 10,520 common shares on 26 June 2025. The option carries an exercise price of $44.04 and expires on 26 June 2035. Vesting occurs in twelve equal monthly installments over one year starting on the grant date. No common shares were bought or sold; this is purely an equity-based compensation award that increases Mr. Mitchell’s derivative holdings to 10,520 options, all held directly. The transaction is routine and designed to align director incentives with shareholder interests, with minimal immediate balance-sheet or ownership impact on PRAX.

Insights

Financial Analyst

TL;DR: Routine option grant; aligns incentives, negligible market impact.

The Form 4 shows a standard director compensation action—a 10,520-share option at $44.04. No shares changed hands, so cash flow and share count are unaffected. The grant size is immaterial relative to PRAX’s total shares outstanding, suggesting limited dilution risk. Because vesting spans only one year, alignment occurs quickly, but investors should note that true value depends on future share-price appreciation above $44.04. Overall, this filing is informational rather than market-moving.

Corporate Governance Expert

TL;DR: Standard equity compensation; governance-compliant, not impactful.

The option grant follows typical board-compensation practice: a ten-year term, reasonable size, and clearly disclosed vesting schedule. There is no evidence of accelerated vesting, repricing, or 10b5-1 complications. Governance frameworks view such grants as best practice for aligning director interests with shareholders. Absent additional insider buying or selling, the disclosure has neutral significance for governance risk assessments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MITCHELL DEAN J

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$44.04	06/26/2025		A		10,520		(1)	06/26/2035	Common Stock	10,520	$0	10,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PRAX report on 26 June 2025?

PRAX disclosed that director Dean J. Mitchell received a stock option grant for 10,520 shares at an exercise price of $44.04.

How many shares are covered by the option granted to Dean J. Mitchell?

The option covers 10,520 common shares.

What is the exercise price and expiration date of the option?

The option’s exercise price is $44.04 and it expires on 26 June 2035.

When will the PRAX option granted on 26 June 2025 vest?

It vests in twelve equal monthly installments over one year beginning on 26 June 2025.

Does the Form 4 indicate any sale of PRAX shares by the director?

No. The filing reports only an option grant; no shares were purchased or sold.